These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36034802)

  • 21. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
    Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of the influencing factors of recombinant human growth hormone effect in the children with Turner syndrome].
    Li J; Wu W; Liang Y; Luo XP
    Zhonghua Er Ke Za Zhi; 2018 Nov; 56(11):866-870. PubMed ID: 30392213
    [No Abstract]   [Full Text] [Related]  

  • 23. The pre-treatment characteristics and evaluation of the effects of recombinant human growth hormone therapy in children with growth hormone deficiency and celiac disease or inflammatory bowel disease.
    Witkowska-Sędek E; Labochka D; Majcher A; Pyrżak B
    Cent Eur J Immunol; 2018; 43(1):69-75. PubMed ID: 29736148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
    Soliman AT; Yassin MA; De Sanctis V
    Acta Biomed; 2018 Feb; 89(2-S):27-32. PubMed ID: 29451226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
    Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association between growth response to growth hormone and baseline body composition of children with growth hormone deficiency.
    Esen I; Demirel F; Tepe D; Kara O; Koc N
    Growth Horm IGF Res; 2013 Oct; 23(5):196-9. PubMed ID: 23890535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth Responses During 3 Years of Growth Hormone Treatment in Children and Adolescents With Growth Hormone Deficiency: Comparison Between Idiopathic, Organic and Isolated Growth Hormone Deficiency, and Multiple Pituitary Hormone Deficiency.
    Lim HH; Kim YM; Lee GM; Yu J; Han HS; Yu J
    J Korean Med Sci; 2022 Mar; 37(11):e90. PubMed ID: 35315601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the Influence of High-Dose rhGH Therapy on Serum Vitamin D and IGF-1 Levels in School-Age Children with Idiopathic Short Stature.
    Li J; Zhang X; Xie S; Feng S; Niu M
    Evid Based Complement Alternat Med; 2021; 2021():5776487. PubMed ID: 34737778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PEGylated Recombinant Human Growth Hormone Jintrolong
    Wu W; Zhou J; Wu C; Zhou Q; Li X; Zhang Y; Zuo C; Yin J; Hou L; Wang S; Gao H; Luo T; Jin L; Zhong E; Wang Y; Luo X
    Front Endocrinol (Lausanne); 2022; 13():821588. PubMed ID: 35909512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
    Hou L; Chen ZH; Liu D; Cheng YG; Luo XP
    Drug Des Devel Ther; 2016; 10():13-21. PubMed ID: 26719670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children.
    Hou L; Liang Y; Wu W; Lin HH; Luo XP; Ying YQ
    Growth Horm IGF Res; 2020; 53-54():101331. PubMed ID: 32777706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Controlled Phase 3 Study on the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Idiopathic Short Stature.
    Yuan J; Fu J; Wei H; Zhang G; Xiao Y; Du H; Gu W; Li Y; Chen L; Luo F; Zhong Y; Gong H
    Front Endocrinol (Lausanne); 2022; 13():864908. PubMed ID: 35573994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment.
    Soliman A; Rogol AD; Elsiddig S; Khalil A; Alaaraj N; Alyafie F; Ahmed H; Elawwa A
    J Pediatr Endocrinol Metab; 2021 Oct; 34(10):1263-1271. PubMed ID: 34291621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of different doses of recombinant human growth hormone in the treatment of short stature in children born small for gestational age].
    Qie D; Yang F
    Zhongguo Dang Dai Er Ke Za Zhi; 2016 Mar; 18(3):247-53. PubMed ID: 26975824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data.
    Romer T; Zabransky M; Walczak M; Szalecki M; Balser S
    Biol Ther; 2011; 1(1):5. PubMed ID: 24392295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
    Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basal characteristics and first year responses to human growth hormone (GH) vary according to diagnostic criteria in children with non-acquired GH deficiency (naGHD): observations from a single center over a period of five decades.
    Ranke MB; Schweizer R; Binder G
    J Pediatr Endocrinol Metab; 2018 Nov; 31(11):1257-1266. PubMed ID: 30332395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No Improvement of Adult Height in Non-growth Hormone (GH) Deficient Short Children with GH Treatment.
    Tanaka T; Fujieda K; Yokoya S; Shimatsu A; Tachibana K; Tanaka H; Tanizawa T; Teramoto A; Nagai T; Nishi Y; Hasegawa Y; Hanew K; Fujita K; Horikawa R; Takada G; Miyashita M; Ohno T; Komatsu K
    Clin Pediatr Endocrinol; 2006; 15(1):15-21. PubMed ID: 24790315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR).
    Rothenbuhler A; Esterle L; Gueorguieva I; Salles JP; Mignot B; Colle M; Linglart A
    Growth Horm IGF Res; 2017 Oct; 36():11-15. PubMed ID: 28822957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Final height in children with idiopathic growth hormone deficiency treated with a fixed dose of recombinant growth hormone.
    Rachmiel M; Rota V; Atenafu E; Daneman D; Hamilton J
    Horm Res; 2007; 68(5):236-43. PubMed ID: 17396034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.